page_title: Epitopoietic Research Corporation
section_title: Leadership
hierarchical_section_title: Epitopoietic Research Corporation / Leadership
caption_attribution_description: English: CEO and founder of ERC-Belgium. This picture was found on the investor relations page.
context_page_description: Epitopoietic Research Corporation is a Belgian Pharmaceutical company developing ERC1671, a treatment for Glioblastoma multiforme, the most aggressive form of brain cancer. In 2019, ERC became the first pharmaceutical company to provide treatment under the US Federal Right-to-try law.
context_section_description: Apostolos Stathopoulos (Co-Founder, CEO) is an MD/PhD Neurosurgeon trained in Belgium. He is Chief of Neurosurgery Service at the Henry Dunant Hospital in Athens, Greece; Visiting Professor at the Department of Cell Biology and Immunology of Wageningen University and Adjunct Associate Professor of Neurological Surgery at the Keck School of Medicine of the University of Southern California. He serves as Co-Director of International Immunotherapy Cancer Center. For pioneering treatment under US Federal Right-To-Try laws, Stathopoulos was named humanitarian of the year by the Abigail Alliance.
  Thomas Chen (Co-Founder, CMO) is an MD/PhD Neurosurgeon and Professor at the University of Southern California. He is one of the few fellowship trained spinal surgeons focused on spine cancer.  
  Virgil Schijns, PhD (Chief Scientific Officer) is the Registered Qualified Person for Gliovac/ERC1671 in the EU.
  Joe Elliot is the head of ERC-USA, ERC's US Subsidiary.
  Vince Dell, Co-Founder ERC-USA and CFO.
  Dr. Bernard Alliaume, Co-Founder and CAO.
  Bernard Quester, Vice-President.
caption: Apostolos Stathopoulos, CEO of Epitopoietic Research Corporation
exif: {}